Výsledky vyhledávání

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Autor: M. von Mehren, Jonathan D. Cheng, E. Temmer, Z. Yuan, F. G. Renshaw, P. Zannikos, E. Bayever, Roger B. Cohen, Russell J. Schilder, T. M. Cardoso

To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies.Entry criteria for th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d812f4037f378e4b2513d45abb0932d4
https://europepmc.org/articles/PMC2598415/

Zobrazit plný text záznamu

647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

Autor: Cindy L. O'Bryant, F. Fox, E. Temmer, S. G. Eckhardt, L.Q. Chow, Lia Gore, H. Youssoufian, D.R. Camidge, Sami Diab, R.B. Cohen

Publikováno v: European Journal of Cancer Supplements. 4:195

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e92fae7471eb92dce162d9583abca904
https://doi.org/10.1016/s1359-6349(06)70652-8

Zobrazit plný text záznamu

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

Autor: L. Maloney, S. Brown, R.B. Cohen, C. Morris, A. Adjei, J. Molina, E. Temmer, S. Hariharan, S. G. Eckhardt, Wilbur A. Franklin

Publikováno v: European Journal of Cancer Supplements. 4:12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::91ffcbd1fc0ba59e98cd4459521abe46
https://doi.org/10.1016/s1359-6349(06)70031-3

Zobrazit plný text záznamu

Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies

Autor: M. von Mehren, D. Buck, Yusri A. Elsayed, E. Temmer, Roger B. Cohen

Publikováno v: Journal of Clinical Oncology. 24:2068-2068

2068 Background: T is a novel cytotoxic agent that binds to the DNA minor groove and is active in several tumor types. The objective of this study is to determine the maximum tolerated dose (MTD) of the combination. Other objectives include safety an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66e6aaea7f92ba2cb9553fad5179a86d
https://doi.org/10.1200/jco.2006.24.18_suppl.2068

Zobrazit plný text záznamu

A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

Autor: Roger B. Cohen, Cindy L. O'Bryant, E. Temmer, Floyd Fox, T. Katz, A. Ervin-Haynes, Sami Diab, Laura Q.M. Chow, Lia Gore, D.R. Camidge, S. G. Eckhardt

Publikováno v: Journal of Clinical Oncology. 24:3032-3032

3032 Background: Anti-VEGFR2 antibodies are effective in a variety of preclinical leukemia and solid tumor models. IMC-1121B is a fully human anti-VEGFR2 IgG1 Mab. Methods: Cohorts of 3–6 pts (ECOG PS ≤ 2) with advanced cancer and no significant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee1232cbd055e5e452ce9f5c2173cb6c
https://doi.org/10.1200/jco.2006.24.18_suppl.3032

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání